oncogenex.com oncogenex.com

oncogenex.com

Welcome to OncoGeneX | OncoGenex Pharmaceuticals Inc

Scientific Publications and Presentations. Scientific Publications and Events. Treatment failure attributed to resistance is a major problem in medical oncology. Across tumor types, the majority of patients with cancer are likely to face treatment resistance at some point. Thursday, Jul 30 2015. OncoGenex to Report Second Quarter 2015 Financial Results on August 13, 2015. Monday, Jul 13 2015. Wednesday, Jun 10 2015. FDA Agrees with OncoGenex' Phase 3 AFFINITY Protocol Amendment. See More Recent News.

http://www.oncogenex.com/

WEBSITE DETAILS
SEO
PAGES
SIMILAR SITES

TRAFFIC RANK FOR ONCOGENEX.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

September

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Friday

TRAFFIC BY CITY

CUSTOMER REVIEWS

Average Rating: 4.0 out of 5 with 2 reviews
5 star
0
4 star
2
3 star
0
2 star
0
1 star
0

Hey there! Start your review of oncogenex.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

Desktop Preview Tablet Preview Mobile Preview

LOAD TIME

CONTACTS AT ONCOGENEX.COM

ONCOGENEX TECHNOLOGIES INC.

SUSAN TEES

SUI●●●401

1001 W●●●●●●OADWAY

VAN●●●VER , BC, V6H 4B1

CA

1.60●●●●3678
ST●●●@ONCOGENEX.COM

View this contact

ONCOGENEX TECHNOLOGIES INC.

SUSAN TEES

SUI●●●401

1001 W●●●●●●OADWAY

VAN●●●VER , BC, V6H 4B1

CA

1.60●●●●3678
ST●●●@ONCOGENEX.COM

View this contact

ONCOGENEX TECHNOLOGIES INC.

KEVIN NOUWENS

1522 ●●●●●● PL SE

BO●●LL , WA, 98021

US

1.42●●●●1530
KN●●●●●●@ONCOGENEX.COM

View this contact

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

DOMAIN REGISTRATION INFORMATION

REGISTERED
2004 May 18
UPDATED
2013 January 28
EXPIRATION
EXPIRED REGISTER THIS DOMAIN

BUY YOUR DOMAIN

Network Solutions®

DOMAIN AGE

  • 21

    YEARS

  • 1

    MONTHS

  • 0

    DAYS

NAME SERVERS

1
dns1.anhosting.com
2
dns2.anhosting.com

REGISTRAR

DOMAINPEOPLE, INC.

DOMAINPEOPLE, INC.

WHOIS : whois.domainpeople.com

REFERRED : http://www.domainpeople.com

CONTENT

SCORE

6.2

PAGE TITLE
Welcome to OncoGeneX | OncoGenex Pharmaceuticals Inc | oncogenex.com Reviews
<META>
DESCRIPTION
Scientific Publications and Presentations. Scientific Publications and Events. Treatment failure attributed to resistance is a major problem in medical oncology. Across tumor types, the majority of patients with cancer are likely to face treatment resistance at some point. Thursday, Jul 30 2015. OncoGenex to Report Second Quarter 2015 Financial Results on August 13, 2015. Monday, Jul 13 2015. Wednesday, Jun 10 2015. FDA Agrees with OncoGenex' Phase 3 AFFINITY Protocol Amendment. See More Recent News.
<META>
KEYWORDS
1 jump to navigation
2 search form
3 about us
4 senior management
5 board of directors
6 news
7 careers
8 patients
9 prostate cancer trials
10 bladder cancer trials
CONTENT
Page content here
KEYWORDS ON
PAGE
jump to navigation,search form,about us,senior management,board of directors,news,careers,patients,prostate cancer trials,bladder cancer trials,lung cancer trials,pancreatic cancer trials,patient resources,physicians,custirsen,apatorsen,other pipeline
SERVER
nginx
CONTENT-TYPE
utf-8
GOOGLE PREVIEW

Welcome to OncoGeneX | OncoGenex Pharmaceuticals Inc | oncogenex.com Reviews

https://oncogenex.com

Scientific Publications and Presentations. Scientific Publications and Events. Treatment failure attributed to resistance is a major problem in medical oncology. Across tumor types, the majority of patients with cancer are likely to face treatment resistance at some point. Thursday, Jul 30 2015. OncoGenex to Report Second Quarter 2015 Financial Results on August 13, 2015. Monday, Jul 13 2015. Wednesday, Jun 10 2015. FDA Agrees with OncoGenex' Phase 3 AFFINITY Protocol Amendment. See More Recent News.

SUBDOMAINS

ir.oncogenex.com ir.oncogenex.com

OncoGenex Pharmaceuticals, Inc. - Investor Relations

Scientific Publications and Presentations. Scientific Publications and Events. Aug 4, 2016. OncoGenex Second Quarter 2016 Conference Call. Aug 16, 2016. Oct 13, 2016. OncoGenex ENSPIRIT Trial Conference Call. Exploring New Compounds to Meet the Challenge of Cancer Treatment Resistance. Phase 2 in bladder, lung, pancreatic and prostate cancers. Role of Hsp27 and Apatorsen (OGX-427). Aug 1, 2017. Achieve Life Sciences Announces Closing of Merger with OncoGenex Pharmaceuticals. Jun 13, 2017. May 15, 2017.

INTERNAL PAGES

oncogenex.com oncogenex.com
1

Pancreatic Cancer Trials | OncoGenex Pharmaceuticals Inc

http://oncogenex.com/patients/pancreatic-cancer-trials

Scientific Publications and Presentations. Scientific Publications and Events. Phase 2 Clinical Trial in Metastatic Pancreatic Cancer. Rainier is an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating apatorsen. Enrollment Completed. Learn more. About the Rainier Trial. Abraxane is a registered trademark of Celgene Corporation. Scientific Publications and Presentations. Scientific Publications and Events. OncoGenex focuses on diverse molecular entities that target mechanisms o...

2

Other Pipeline | OncoGenex Pharmaceuticals Inc

http://oncogenex.com/physicians/other-pipeline

Scientific Publications and Presentations. Scientific Publications and Events. In addition to our product candidates custirsen. In Phase 3 development, and apatorsen (OGX-427). In Phase 2 development, our investigational compound OGX-225 is in pre-clinical development. OGX-225 is a second generation antisense drug candidate designed to inhibit the production of Insulin Growth Factor Binding Proteins -2 and -5 (IGFBP-2, IGFBP-5), two proteins that when overexpressed affect the growth of cancer cells.

3

Privacy Policy | OncoGenex Pharmaceuticals Inc

http://oncogenex.com/node/51

Scientific Publications and Presentations. Scientific Publications and Events. Placeholder text (you can add a block title above). The Information We Gather. We gather traffic patterns and site usage information such as browser type, referring URL, and IP address, to help us develop the design and layout of the site. This information is not linked to any personally identifiable information about you. Scientific Publications and Presentations. Scientific Publications and Events. OncoGenex Pharmaceuticals ...

4

Careers with Us | OncoGenex Pharmaceuticals Inc

http://oncogenex.com/content/careers-us

Scientific Publications and Presentations. Scientific Publications and Events. Placeholder text (you can add a block title above). Why Work At OncoGenex? Do you want to work in an energetic, open and collaborative environment where you have the opportunity to be an integral part of a highly experienced and dedicated team? Do you have a passion for work that improves the lives of cancer patients? Competitive salary based on experience. Performance-based incentive bonus plan. OncoGenex is uniquely focused ...

5

Welcome to OncoGeneX | OncoGenex Pharmaceuticals Inc

http://oncogenex.com/content/welcome-oncogenex

Scientific Publications and Presentations. Scientific Publications and Events. Treatment failure attributed to resistance is a major problem in medical oncology. Across tumor types, the majority of patients with cancer are likely to face treatment resistance at some point. Tuesday, Aug 16 2016. OncoGenex Announces Results from the Phase 3 AFFINITY Trial of Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer. Thursday, Aug 4 2016. Thursday, Jul 21 2016. See More Recent News. OncoGenex is u...

UPGRADE TO PREMIUM TO VIEW 14 MORE

TOTAL PAGES IN THIS WEBSITE

19

LINKS TO THIS WEBSITE

ir.oncogenex.com ir.oncogenex.com

OncoGenex Pharmaceuticals, Inc. - Management & Board

http://ir.oncogenex.com/bios.cfm

Scientific Publications and Presentations. Scientific Publications and Events. Gt Management and Board. President and Chief Executive Officer. Dr Cindy Jacobs Ph.D, MD. Executive Vice President and Chief Medical Officer. Vice President and Chief Financial Officer. Vice President, Clinical Operations. Patricia S Stewart MD. Vice President, Clinical Development. Vice President, Marketing and Corporate Communications. Jack Goldstein Ph.D. Member of the Audit Committee. Member of the Compensation Committee.

ir.oncogenex.com ir.oncogenex.com

OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Continues Following Completion of Final Futility Survival Analysis (NASDAQ:OGXI)

http://ir.oncogenex.com/releasedetail.cfm?ReleaseID=921669

Laquo; Previous Release. Next Release ». July 13, 2015. OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Continues Following Completion of Final Futility Survival Analysis. Rigorous Criteria Met, Trial in NSCLC Patients Proceeds as Planned. VANCOUVER, British Columbia. July 13, 2015. OncoGenex Pharmaceuticals, Inc. Two interim analyses were originally planned to evaluate whether to stop the trial for futility. OncoGenex filed an amendment with the. US Food and Drug Administration. Amending the stat...

resourcefulhr.com resourcefulhr.com

Resourceful HR Clients | Resourceful HR | Seattle, WA

http://www.resourcefulhr.com/testimonials/resourceful-hr-clients.html

Welcome to Resourceful HR. SPUD - Outsourced HR and Recruiting. Buzzbee Technology Marketing - Recruiting. Immune Design - Outsourced HR and Recruiting. Ldquo;From the very start, Resourceful HR took the time to get to know us, our business and our culture.In addition to being knowledgeable about all aspects of HR, Resourceful HR is also extremely productive, detail-oriented and efficient, which is so important in our fast-paced environment. Alma E. Tcruz. Former Sr. Recruiter, Human Resources.

higbio.com higbio.com

H.I.G. BioHealth Partners Portfolio Company

http://higbio.com/portfolio/company/145

Visit H.I.G. Capital. OncoGenex Technologies, based in Vancouver, is a clinical-stage biotechnology company developing targeted therapeutics that address treatment resistance in cancer patients. OncoGenex was spun-out from the Prostate Centre at Vancouver General Hospital, western Canada’s largest hospital and the principal teaching hospital of the University of British Columbia. For more information visit: http:/ www.oncogenex.com/. Miami, FL 33131.

newswire.ca newswire.ca

OncoGenex Announces Data to be Presented at ASCO 2015 Annual Meeting

http://www.newswire.ca/en/story/1540231/oncogenex-announces-data-to-be-presented-at-asco-2015-annual-meeting

Register for my CNW. Send a News Release. Acquisitions, Mergers and Takeovers. Banking and Financial Services. Register for my CNW. See more news releases in. Health Care and Hospitals. Clinical Trials and Medical Discoveries. OncoGenex Announces Data to be Presented at ASCO 2015 Annual Meeting. BOTHELL, Wash. and."/. Survival Benefit Seen with Custirsen and Apatorsen in Patients with Greatest Therapeutic Need. May 20, 2015. CNW/ -  OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI. From May 29-June 2. Presi...

ir.oncogenex.com ir.oncogenex.com

OncoGenex Pharmaceuticals, Inc. - Email Alert Subscription

http://ir.oncogenex.com/profile.cfm

Scientific Publications and Presentations. Scientific Publications and Events. Gt Email Alert Subscription. Step 1 of 3: Select Options. You may automatically receive OncoGenex Pharmaceuticals, Inc. financial information by email. Please enter your preferences for email notifications below and click "Continue" to enter your contact information on the next page. If you have already signed up and would like to review your subscription, click here. Quarterly and Annual Reports. All Events and Webcasts.

hrlaunchpad.com hrlaunchpad.com

Resourceful HR Clients | Resourceful HR | Seattle, WA

http://www.hrlaunchpad.com/testimonials/resourceful-hr-clients.html

Welcome to Resourceful HR. SPUD - Outsourced HR and Recruiting. Buzzbee Technology Marketing - Recruiting. Immune Design - Outsourced HR and Recruiting. Ldquo;Resourceful HR managed the overall merger and acquisition process well - helping to keep us on track and efficient during the transaction. Their excellent service enabled me to focus on the most crucial aspects of the deal and thereby ensured a high quality outcome for everyone. Some of Our Clients. California Life Sciences Association.

new.resourcefulhr.com new.resourcefulhr.com

Resourceful HR Clients | Resourceful HR | Seattle, WA

http://new.resourcefulhr.com/testimonials/resourceful-hr-clients.html

Welcome to Resourceful HR. SPUD - Outsourced HR and Recruiting. Buzzbee Technology Marketing - Recruiting. Immune Design - Outsourced HR and Recruiting. Ive worked with several recruiters in the past and by far working with Resourceful HR has been the best experience. They honed in on what we were looking for and found candidates who were spot-on. We couldn’t have generated the amount of leads, not even close, without their assistance. Some of Our Clients. California Life Sciences Association.

pctriadd.com pctriadd.com

Partners | PC-Triadd

http://www.pctriadd.com/about-us/partners

As with any successful research enterprise the key to success is establishing and maintaining strong networks and partnerships with local, national, and international collaborators, as well as funders, patients and benefactors. Our valuable partners include:. UBC Faculty of Medicine. UBC Department of Urologic Sciences. Canada Foundation for Innovation. Canadian Institutes of Health Research. The Centre for Drug Research and Development. Provincial Health Services Authority. The Terry Fox Foundation.

UPGRADE TO PREMIUM TO VIEW 126 MORE

TOTAL LINKS TO THIS WEBSITE

135

SOCIAL ENGAGEMENT



OTHER SITES

oncogenetics.org oncogenetics.org

oncogenetics.org

The domain oncogenetics.org is for sale. To purchase, call Afternic.com at 1 781-373-6847 or 855-201-2286. Click here for more details.

oncogenetique.curie.fr oncogenetique.curie.fr

Institut Curie

A propos du site. La consultation en psycho-oncologie. Pourquoi voir un psychologue. Le vécu de la famille. Vos interlocuteurs au Service d'Oncogénétique. L’assistante médicale participe au bon déroulement de la consultation de génétique mais également à la préparation de cette…. Le psycho-oncologue est un psychologue ou un psychiatre qui travaille auprès de patients atteints de cancer et a…. Bull; MENTIONS LEGALES. 2013 - Institut Curie. Conception and réalisation : www.multimedia-sorbonne.com.

oncogenetix.ro oncogenetix.ro

Account Suspended

This Account has been suspended. Contact your hosting provider for more information.

oncogenex-pharmaceuticals.com oncogenex-pharmaceuticals.com

Site not found · DreamHost

Well, this is awkward. The site you're looking for is not here. Is this your site?

oncogenex.ca oncogenex.ca

Site not found · DreamHost

Well, this is awkward. The site you're looking for is not here. Is this your site?

oncogenex.com oncogenex.com

Welcome to OncoGeneX | OncoGenex Pharmaceuticals Inc

Scientific Publications and Presentations. Scientific Publications and Events. Treatment failure attributed to resistance is a major problem in medical oncology. Across tumor types, the majority of patients with cancer are likely to face treatment resistance at some point. Thursday, Jul 30 2015. OncoGenex to Report Second Quarter 2015 Financial Results on August 13, 2015. Monday, Jul 13 2015. Wednesday, Jun 10 2015. FDA Agrees with OncoGenex' Phase 3 AFFINITY Protocol Amendment. See More Recent News.

oncogenexpharm.com oncogenexpharm.com

oncogenexpharm.com

This domain has expired. Click here to renew.

oncogenic.com oncogenic.com

oncogenic.com

The Sponsored Listings displayed above are served automatically by a third party. Neither the service provider nor the domain owner maintain any relationship with the advertisers. In case of trademark issues please contact the domain owner directly (contact information can be found in whois).

oncogenicity.com oncogenicity.com

Site title | Just another WordPress site

Just another WordPress site. Welcome to WordPress. This is your first post. Edit or delete it, then start blogging! This entry was posted in Uncategorized. June 21, 2013. Proudly powered by WordPress.

oncogenics.com oncogenics.com

Web Page Under Construction

This Site Is Under Construction and Coming Soon. This Domain Is Registered with Network Solutions.

oncogenome.com oncogenome.com

oncogenome.com

The Sponsored Listings displayed above are served automatically by a third party. Neither the service provider nor the domain owner maintain any relationship with the advertisers. In case of trademark issues please contact the domain owner directly (contact information can be found in whois).